



Minutes

Date Wednesday, 05/01/2022

Time 9:00 AM

To Committee Members

At Virtual via Microsoft Teams

Subject AWERB 3Rs Committee

In Attendance: [REDACTED]

Apologies: [REDACTED]

Minutes - [REDACTED]

1. Minutes

The previous minutes were approved

2. Matters Arising

[REDACTED] discussed the possibility of meeting in person in March.

3. Retrospective Reviews

The committee discussed the following:

[REDACTED] - [REDACTED] Proteostasis in lung disease

- Section 2.5: More details needed about the non-use of the protocols 1 to 3.
- Section 3.1: The committee advises to highlight the publication in the relevant section of the retrospective review (section 4.8)
- Section 3.2: Further information needed on the use of primary human cell to replace animals - Details of the animal reduction number.

[REDACTED] - [REDACTED] Understanding how to exploit the oxygen sensing pathway for therapeutic benefit

Section 2.2: protocol 5, animal's were returned with a severe severity. More information required regarding the reason for this higher severity.

Section 3.7: Several refinements are cited in this section and the committee would like to know if there are any publications or any being prepared highlighting these methods.



- [REDACTED] - [REDACTED] Mechanisms of metabolic disease
- Section 2.1: protocol, 9, 21 and 22 a number of animals returned as “non-recovery”. The protocols were classified as mild or moderate - Further details needed about this.

4. Amendments

5. Severe Severity

6. Severe Severity licence reviews

7. Standard condition 18 reports

8. 3Rs information/reports

[REDACTED] reported that in AOC [REDACTED] informed the committee of SC18 reports from a PPLh who has had 7 repeated incidents due to rapid tumour growth exceeding the 10% body weight limit. The NACWOs from the animal facility are aware of this and are monitoring the issue. In the 3Rs report, the use of restraints has been discussed.

9. Highlights of AWERB Standing meeting*

10. Highlights of January AOC meeting*

11. Any Other Business

- Hydrodynamic tail vein injection <https://www.mirusbio.com/products/in-vivo/transit-qr-delivery-solution> - Discussed briefly as FIO
- Blood sampling via the saphenous vein poster to be reviewed by the committee. (Circulated with meeting documents) Discussed and final version will be circulated.

12. For information only

Date of next meeting: 2nd February 2022

***Items for information only unless un-starred by committee member**